Anticoagulation in the elderly: indications and limitations

  • G. Pinganaud
  • P J. Louvet
  • J P. Emeriau

Abstract

Anticoagulants are not often prescribed in elderly people because of the risk of haemorrhage. But during the last few years, the results of many large controlled double blind trials have been published, which have specified indications. Chronological age by itself is not a contra-indication, the limitations being the diseases associated with ageing.

Keywords

Placebo Aspirin Heparin Warfarin Hull 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Antiplatelets trialists collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Brit Med J, 296, 320–331, 1988. CrossRefGoogle Scholar
  2. 2.
    Aquino JP, Gambier A, Ducros JJ. Prevention of thromboembolic accidents in elderly subjects with FraxiparineR. Second international symposium. Recent pharmacological and clinical data. Bounamoux H, Samama M, Ten Cate JW (Eds). Schattauer, Stuttgart, New York, 189, pp 51–54, 1990.Google Scholar
  3. 3.
    Coon WW, Willis PW. Hemorrhagic complications of anticoagulant therapy. Arch Inter Med 133, 386–392, 1974.CrossRefGoogle Scholar
  4. 4.
    Fuster V, Badinon L, Badinon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 23, 242–250, 1992.Google Scholar
  5. 5.
    Gallus A, Tillet J, Jaskaman J, Mills W, Wycherley A. Safety and efficacity of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 2, 1293, 1986.PubMedCrossRefGoogle Scholar
  6. 6.
    Goldberg RJ, Gore JM, Gurwitz JH, Alpert JS, Brady P, Strohsnitter W, Chen ZY, DALEN JE. The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J 117, 543–549, 1989.Google Scholar
  7. 7.
    Gruppo Italiano Per Lo Studio Delia Streptochinasi Nell’; Infarcto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1, 397–402, 1986. Google Scholar
  8. 8.
    Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general radical in-patients by low dose heparin prophylaxis. Ann Int Med 96, 561–565, 1982.PubMedGoogle Scholar
  9. 9.
    Hsia J, Hamilton WP, Kleiman N. Heparin aspirin reperfusion trial. A comparison between heparin and low dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 323, 1433–1437, 1990.Google Scholar
  10. 10.
    Huber K, Resch T, Rosc D, Probst R, Daindl F, Binder BR. Heparin induced increase of t—PA antigens plasma levels in patients with unstable angina: no evidence for clinical benefits of heparinization during the initial phase of treatment. Thrombos Res 55, 779–784, 1989.CrossRefGoogle Scholar
  11. 11.
    Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 18, 322, 1990.Google Scholar
  12. 12.
    ISIS 2. Collaborative group randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1, 349–360, 1988. Google Scholar
  13. 13.
    Klint CR, Knatterud GL, Stamler H. Persantin aspirin reinfarction study. Part II. Secondary prevention with persantin and aspirin. JACC 7, 251–269, 1986.Google Scholar
  14. 14.
    Landefeld CS, Mac Guire EI, Rosenblatt MW. A bleeding risk index for estimating the possibility of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 89, 569–578, 1990.PubMedCrossRefGoogle Scholar
  15. 15.
    Landefeld CS, Cook EF, Flatley M, Weigberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 82, 703–713, 1987.PubMedCrossRefGoogle Scholar
  16. 16.
    Lodder J, Dennis NS, Van Raak L, Jones LN, Warlow CP. Cooperative study on the value of long term anticoagulation in patients with stroke and non-rheumatic atrial fibrillation. Brit Med J 296, 1435–1438, 1988.CrossRefGoogle Scholar
  17. 17.
    Manciet G, Vergnes C, Vaissie J, Boisseau MR. A study on the efficacy and tolerance of FraxiparineR during long-term therapy on the elderly. A randomized double blind clinical trial. An european multicenter randomized clinical trial. Second international symposium. Recent pharmacological and clinical data. Bounamoux H, Samama M, Ten Cate JW (Eds). Schattauer, Stuttgart, New York, pp 55–59, 1990. Google Scholar
  18. 18.
    Mason JE, Grobee DE, Stampfer MJ et al. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States Physicians. Am J Med 89, 772–776, 1990.CrossRefGoogle Scholar
  19. 19.
    Neri Serneri GG, Gensini GF, Poggesi L, Trotta F, Modesti PA, Boddi M, Leri A, Margheri M, Casolo GC, Bini M et al. Effects of heparin, a3pirin or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet 335, 615–618, 1990. PubMedCrossRefGoogle Scholar
  20. 20.
    Ninet J, Duroux P. Treatment of proximal deep venous thrombosis with the low molecular weight subcutaneous heparin (FraxiparineR) or unfractionated intravenous heparin. An european multicenter randomized clinical trial. Second international symposium. Recent pharmacological and clinical data. Bounamoux H, Samama M, Ten Cate JW (Eds). Schattauer, Stuttgart, New York, 65–75, 1990. Google Scholar
  21. 21.
    Paganin I, Hill A, Chao A, Ross RK, Anderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. Brit Med J 299, 1247–1250, 1989.CrossRefGoogle Scholar
  22. 22.
    Peterson P, Boysen G, Godfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFALSAK Study. Lancet 28, 175–179, 1989.CrossRefGoogle Scholar
  23. 23.
    Prandoni P et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 339, 441–445, 1992.PubMedCrossRefGoogle Scholar
  24. 24.
    Prandoni P, Vigo M, Cattelan AM, Ruol A. The treatment of deep venous thrombosis by fixed doses of a low molecular weight fraction (CY 216). Second international symposium. Recent pharmacological and clinical data. Bounamoux H, Samama M, Ten Cate JW (Eds). Schattauer, Stuttgart, New York, pp 77–80, 1990. Google Scholar
  25. 25.
    Risk Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336, 827–830, 1990.CrossRefGoogle Scholar
  26. 26.
    Scati Group. Randomized controlled trial of subcutaneous calcium heparin in acute myocardial infarction. Lancet 11, 182–186, 1989.Google Scholar
  27. 27.
    Sheehan F, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, Passamani ER, Williams DO, Zaret B et al. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from thrombolysis in myocarcial infarction (TIMI phase 1) trial. Circulation 75, 817–829, 1987.PubMedCrossRefGoogle Scholar
  28. 28.
    Smith P, Arnesen H, Holmie I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 323, 147–152, 1990.PubMedCrossRefGoogle Scholar
  29. 29.
    Stroke prevention in atrial fibrillation study group investigators. Preliminary report of the stroke prevention in atrial fibrillation study. N Engl J Med 322, 863–868, 1990. Google Scholar
  30. 30.
    Telford AM, Wilson C. Trial of heparin versus Atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet, 1225–1228, 1991. Google Scholar
  31. 31.
    The Boston area anticoagulation trial for atrial fibrillation investigators. The effects of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 323, 1501–1511, 1990. Google Scholar
  32. 32.
    The Sixty Plus Reinfarction Study Research Group. A double blind trial to assess long term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 2, 989–993, 1980.Google Scholar
  33. 33.
    Theroux P, Ouimet H, Mac Cans J. Aspirin, heparin or both in unstable angina. N Engl J Med 319, 1105–1111, 1988. PubMedCrossRefGoogle Scholar
  34. 34.
    Thery C. Treatment of pulmonary embolism with CY 216 dose finding study. French study group on FraxiparineR therapy. Second international symposium. Recent pharmacological and clinical data. Bounamoux H, Samama M, Ten Cate JW (Eds). Schattauer, Stuttgart, New York, pp 81–85, 1990. Google Scholar
  35. 35.
    Topol EJ, Califf RM, Kereiakes DJ, George BS. Thrombolysis and angioplasty in myocardial infarction (TAMI) trial. J Am Coll Cardiol 10, 65B–74B, 1987.PubMedCrossRefGoogle Scholar
  36. 36.
    Walker AM, Jick H. Prediction of bleeding during heparin therapy. JAMA 244, 1209–1212, 1980.PubMedCrossRefGoogle Scholar
  37. 37.
    Wessler S. Anticoagulants in the prevention of embolic stroke. Part I. Geriatrics 42(2), 29–35, 1987.Google Scholar
  38. 38.
    White H, Cross D, Scott M, Norris R. Comparison of effects of thrombolytic therapy on left ventricular function in patients over with those under 60 years of age. Am J Cardiol 67, 913–918, 1991.PubMedCrossRefGoogle Scholar
  39. 39.
    Witzen AR, Tussen JG, Devries WA, Loeliger EA, Roos J. Risk of long term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1, 64–68, 1982.Google Scholar
  40. 40.
    Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. Treatment following myocardial infarction. JAMA 260, 2088–2093, 1988.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • G. Pinganaud
  • P J. Louvet
  • J P. Emeriau

There are no affiliations available

Personalised recommendations